---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002538"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:56:01.339019+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q4 net loss $93.2M; wet AMD pivotal trial misses primary endpoint

## Summary
- Phase 2b/3 KSI-301 study in wet AMD did not meet non-inferiority vs aflibercept for extended dosing.
- 59% of KSI-301 patients achieved 5-month dosing; safety profile acceptable with no new signals.
- Q4 net loss $93.2M ($1.79/share) vs $46.6M a year ago; full year net loss $267.0M.
- R&D expenses $75.6M in Q4, up from $37.4M, driven by clinical trial and manufacturing costs.
- Cash and equivalents $731.5M; BEACON RVO top-line data expected Q3 2022.

## SEC filing metadata
- accession: 0000950170-22-002538
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017022002538/0000950170-22-002538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017022002538/kod-20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002538
- JSON: https://secwatch.observer/filing/0000950170-22-002538.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.